Gross proceeds were $460 million before underwriting discounts and offering expenses with the shares sold at $16 each, the clinical-stage cardiovascular drug developer said Monday in a statement.

http://www.mtnewswires.com
Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.